TORL Biotherapeutics, LLC’s Post

View organization page for TORL Biotherapeutics, LLC, graphic

1,862 followers

TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline

TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline

prnewswire.com

Congratulations to the TORL team bringing UCLA therapies to the market.

Bin Li

Project Management/CMC Management

6mo

Congratulations to the TORL Team!

Like
Reply
Stephen Scheer, MBA

Sales Leader/Healthcare/Technology/Key Accounts

6mo

Congrats Team TORL!

Like
Reply
Jayne Butler

Director of Strategic Initiatives at Leaderboard Branding

6mo

Congratulations to the TORL BioTherapeutics Team!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics